Lantheus Holdings (LNTH) Non-Current Receivables (2015 - 2026)
Lantheus Holdings (LNTH) reported Non-Current Receivables of $92.1 million for Q1 2026, up 3566.52% quarter-over-quarter from $2.5 million in Q4 2015.
Lantheus Holdings (LNTH) Non-Current Receivables (2015 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 2 years of Non-Current Receivables data on file, last reported at $92.1 million in Q1 2026.
- Non-Current Receivables for Q1 2026 came in at $92.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $92.1 million (changed N/A YoY), and the FY2015 annual result was $2.5 million, changed N/A from the prior year.
- Non-Current Receivables improved to $92.1 million in Q1 2026 per LNTH's latest filing, from $2.5 million in the prior quarter.
- Over five years, Non-Current Receivables peaked at $92.1 million in Q1 2026 and troughed at $92.1 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 92.10 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.10 Mn |
| Dec 31, 2015 | 2.51 Mn |